Table 4

Effect of PSC 833 on the tissue-to-plasma concentration ratio of [3H]DGX

Dose of PSC 833
Control0.1 mg/kg0.3 mg/kg3 mg/kg
Brain0.335  ± 0.0270.306  ± 0.0470.428  ± 0.0401.64  ± 0.454-160
Liver9.34  ± 1.307.35  ± 1.5611.4  ± 3.510.1  ± 1.7
Kidney2.38  ± 0.292.46  ± 0.203.42  ± 0.452.42  ± 0.26
Adrenal103  ± 298.2  ± 24.6128  ± 1991.4  ± 21.4
Intestine1.40  ± 0.171.15  ± 0.081.52  ± 0.151.05  ± 0.16
Spleen1.24  ± 0.061.18  ± 0.491.89  ± 0.331.46  ± 0.06
Lung2.48  ± 0.991.42  ± 0.312.43  ± 0.392.33  ± 0.48

[3H]DGX was administered i.v. to rats that had received an i.v. injection of PSC 833 (0, 0.1, 0.3, and 3 mg/kg) 30 min before the experiments. At 6 h after administration of [3H]DGX, the tissue-to-plasma concentration ratio was determined. Amount of [3H]DGX in the plasma and all tissues examined was determined with HPLC. Results are given as the mean ± S.E. of four independent experiments.

  • 4-160p < .01, significantly different from control by ANOVA followed by Fisher’s t test.